Biotech's usual Q4 strength ahead of JPM season makes aggressive rallies in smaller names highly likely. ARKG is starting to break out, and PDS Biotechnology is showing multiple buy signals. If ARKG keeps running as expected, Nautilus Biotechnology, PDS Biotechnology and Quantum-Si could reasonably rally toward about $10 soon; broken chart structures would invalidate that view. x.com  x.com 

Nautilus Biotechnology could become extraordinarily important to oncology by reading intact proteoform states across cancer's redundant signaling pathways. Before-and-after tumor measurements could train AI to find the smallest effective, tumor-specific drug combination beyond mutation-guided care. It has not shown it can map every clinically relevant cancer proteoform or prescribe curative combinations. AI-biology companies must buy Nautilus now or face painfully compressed margins. x.com  x.com 

Nautilus Biotechnology remains too speculative and faces eventual Nasdaq delisting if it cannot hold above $1. A price floor just under $1 after its collapse looks technically supportive, and there are early signs of commercial interest, but it is still a wild card. x.com 

Zeta Global could become a much larger company: at Zeta Live, executives with over $200 billion of decision-making power discussed what its keynote meant for their own companies, a firsthand sign of potential enterprise interest. Its 120% net dollar retention suggests existing customers get value, though future growth is uncertain. x.com 

Voyager's single-molecule approach could make Nautilus the most asymmetric proteomics bet if it works. Quarterly grant revenue of about $0.2m against over $10m consumed leaves it reliant on capital; a $125m ATM risks dilution. Repeated slips make the mid-2027 launch less likely to hold; independent customer validation and a sales channel are absent. Adoption could justify billions; delay or low-price issuance could send shares below $2 again. Tempus AI remains the preferred larger holding. x.com 

Nautilus Biotechnology is wildly overvalued at about $250M on just $190K of trailing-12-month revenue, a price richer than early-stage VC. That rebuts @alc2022's case that it owns the read layer for the proteome and could return 100-1,000x. x.com 

Zeta Global's acquisition of Senso strengthens its AI moat by adding AI engineering and frontier-model connectivity to its Intelligent AI Infrastructure. No software company is building an AI moat like Zeta, so the stock should go higher; more details are due at Zeta Live. x.com 

Zeta Global is compounding with software-like durability and adtech-scale growth while shareholders get a growing share of it. It has posted 21+ straight quarters of 20%+ organic growth on a run rate just over $1B, tracking toward about $2B. Pipeline per rep is up 100% on only 11% more sales headcount. Its Athena AI product is used monthly by 40% of top customers. The Palantir partnership adds incremental revenue, and buybacks take 50%+ of cash flow with dilution near zero. x.com 

Zeta Global looks unappealing because, after years in business, it is supposed to be highly profitable but isn't, and the risk-reward is not great. It is not the kind of super-high-growth company in a hot sector worth favoring, though it could still outperform. A post the author replies to argues Zeta benefits from AI and posted a monster quarter yet trades as if it will fail. x.com 

Zeta Global's entry into the FedRAMP Marketplace could open a new federal-agency revenue channel beyond commercial enterprise customers. Its government-focused marketing platform is still in initial implementation and has not earned certification. This prospective expansion adds to the long-term bullish case, alongside its existing Palantir partnership. x.com